Loading clinical trials...
Loading clinical trials...
As the population ages, the growing prevalence of age-related diseases is creating substantial challenges for healthcare systems worldwide. Current therapeutic strategies often target individual diseases and decrease mortality without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process itself could prevent, delay, or manage the severity of multiple age-related diseases concurrently, thereby improving overall healthspan and reducing healthcare burdens. Emerging research highlights several interconnected hallmarks of aging, such as mitochondrial dysfunction, chronic inflammation, impaired autophagy, and immune dysregulation, as modifiable through targeted interventions. Precision geromedicine represents a paradigm shift in addressing these processes, combining baseline diagnostics with individualized treatment strategies that adapt over time based on patient response. This approach integrates lifestyle modifications, dietary supplements, and pharmacological agents to optimize physical, cognitive, and immune function across the lifespan .
This study aims to evaluate the effectiveness and feasibility of a personalized, multimodal precision geromedicine intervention targeting key hallmarks of aging. We hypothesize that an 8-week intervention combining lifestyle modification and targeted supplementation will improve biological and clinical markers of aging in middle-aged to older (50-80 years) adults. Participants within this age range are chosen because they are more likely to encounter early declines in muscle, immune, and cognitive functions, while still being responsive to preventive measures. The criteria for inclusion concentrate on individuals scoring below the 75th percentile for normative values in VO₂peak and cognitive performance. This demographic presents an optimal opportunity for interventions aimed at prolonging healthspan and postponing functional decline. Hypothesis The multimodal precision geromedicine intervention will be feasible to conduct and effective in improving muscle, cognitive, and immune function, as well as other biological, clinical, and digital biomarkers of aging in middle aged to older adults.
Age
50 - 80 years
Sex
ALL
Healthy Volunteers
Yes
MD11 Clinical Research Centre, #03-01, 10 Medical Drive, Singapore 117597
Singapore, Singapore, Singapore
Start Date
September 29, 2025
Primary Completion Date
February 23, 2026
Completion Date
June 30, 2026
Last Updated
March 5, 2026
20
ESTIMATED participants
Sleep and dietary counseling
OTHER
Supervised exercise and exergaming program
OTHER
Motivational interviewing
BEHAVIORAL
Whey protein
DIETARY_SUPPLEMENT
Creatine Monohydrate
DIETARY_SUPPLEMENT
Fucoidan
DIETARY_SUPPLEMENT
Urolithin A
DIETARY_SUPPLEMENT
Nicotinamide Mononucleotide (NMN)
DIETARY_SUPPLEMENT
Multivitamin
DIETARY_SUPPLEMENT
Ergothioneine
DIETARY_SUPPLEMENT
Lead Sponsor
National University of Singapore
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05203406